Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

Detalimogene Voraplasmid Produces Complete Responses in BCG-Unresponsive NMIBC With CIS

February 19th 2025

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC

February 18th 2025

Neoadjuvant chemotherapy and concurrent chemoradiation could represent a safe, effective bladder-sparing approach in MIBC.

Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 16th 2025

Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.

Perioperative Durvalumab Shows Benefits in MIBC Irrespective of pCR Status

February 15th 2025

Data spotlighted that the addition of perioperative durvalumab to radical cystectomy and adjuvant chemotherapy improved outcomes in MIBC.

Dato-DXd Prolongs Responses in Pretreated Advanced/Metastatic Urothelial Cancer

February 15th 2025

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer

February 15th 2025

UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC

February 14th 2025

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

Enfortumab Vedotin/Pembrolizumab Elicits Radiographic Responses in Primary UTUC Lesions

February 14th 2025

Enfortumab vedotin, both as monotherapy and in combination with pembrolizumab, demonstrated clinical activity in patients with UTUC lesions.

Real-World Data Show Enfortumab Vedotin Significantly Improves OS in Urothelial Carcinoma

February 14th 2025

Enfortumab vedotin significantly improved outcomes for patients with unresectable or metastatic urothelial carcinoma, according to real-world data.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront

February 10th 2025

Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.

Nogapendekin Alfa Inbakicept Is Under EMA Review for BCG-Unresponsive NMIBC With CIS

January 27th 2025

The EMA has accepted for review an MAA seeking the approval of nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS.

UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC

January 22nd 2025

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

Dr Garje on Unmet Needs in Small Cell Bladder Cancer

January 17th 2025

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

FDA Approval Is Sought for TAR-200 in BCG-Unresponsive High-Risk NMIBC With CIS

January 15th 2025

An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.